机械心脏瓣膜合并颅内出血患者抗凝恢复时机与缺血及出血并发症风险
该回顾性队列研究纳入3家三级医院171例机械心脏瓣膜合并颅内出血患者,发现停用抗凝至少7天可能安全,抗凝恢复时使用静脉肝素桥接与颅内出血扩大风险增加相关。
要点
- 停用抗凝至少7天在机械心脏瓣膜合并颅内出血患者中可能安全。
- 抗凝恢复时使用静脉肝素桥接与颅内出血扩大风险增加相关。
- 接受抗凝逆转治疗的患者未增加血栓栓塞并发症风险。
核心结论
- 颅内出血后停用抗凝至少7天在机械心脏瓣膜患者中可能安全。
- 抗凝恢复期间肝素桥接可能与出血风险增加相关。
研究设计与样本
- 回顾性队列观察性研究,纳入3家三级医院2000年1月1日至2022年7月13日连续收治的机械心脏瓣膜合并颅内出血的成年患者。
- 最终分析共纳入171例患者。
主要发现
- 79.5%的患者接受了抗凝逆转治疗,接受逆转治疗者未增加血栓栓塞并发症风险。
- 停用抗凝时间与缺血性卒中风险无关;仅2例患者在颅内出血后7天内发生卒中,且均有其他主要血栓栓塞危险因素。
- 停用抗凝期间缺血性卒中/短暂性脑缺血发作的发生率低于抗凝恢复后颅内出血扩大的发生率(6.4% vs 9.9%)。
- 发生颅内出血扩大的患者死亡率高于停用抗凝期间发生缺血性卒中的患者(41% vs 9%)。
- 与不桥接重启华法林相比,重启华法林时使用静脉肝素桥接与颅内出血扩大风险增加强烈相关。
关键数值与推荐
- 颅内出血扩大定义为:脑内血肿体积增加三分之一、凸面硬膜下血肿直径增加三分之一,或其他部位颅内出血肉眼明确扩大。
- 停用抗凝期间缺血性卒中/短暂性脑缺血发作发生率为6.4%,抗凝恢复后颅内出血扩大发生率为9.9%。
- 颅内出血扩大患者死亡率为41%,停用抗凝期间缺血性卒中患者死亡率为9%。
临床怎么用
- 颅内出血后停用抗凝至少7天在机械心脏瓣膜患者中可能安全。
- 抗凝恢复期间肝素桥接可能与出血风险增加相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In patients with mechanical heart valves and recent intracranial hemorrhage (ICH), clinicians need to balance the risk of thromboembolism during the period off anticoagulation and the risk of hematoma expansion on anticoagulation. The optimal timing of anticoagulation resumption is unknown. We aimed to investigate the relationship between reversal therapy and ischemic stroke, between duration off anticoagulation and risk of ischemic strokes or systemic embolism and between timing of anticoagulation resumption and risk of rebleeding and ICH expansion. METHODS: We conducted a retrospective cohort observational study in 3 tertiary hospitals. Consecutive adult patients with mechanical heart valves admitted for ICH between January 1, 2000, and July 13, 2022, were included. The primary end points of our study were thromboembolic events (cerebral, retinal, or systemic) while off anticoagulation and ICH expansion after anticoagulation resumption (defined by the following criteria: increase by one-third in intracerebral hematoma volume, increase by one-third in convexity subdural hemorrhage diameter, or visually unequivocal expansion of other ICH locations to the naked eye). RESULTS: A total of 171 patients with mechanical heart valves who experienced ICH were included in the final analysis. Most of the patients (79.5%) received reversal therapy for anticoagulation. Patients who received anticoagulation reversal therapy did not have increased risk of thromboembolic complications. Time off anticoagulation was not associated with risk of ischemic stroke; only 2 patients had a stroke within 7 days of the ICH, and both had additional major risk factors of thromboembolism. The rate of ischemic stroke/transient ischemic attack while off anticoagulation was lower than the rate of ICH expansion once anticoagulation was resumed (6.4% vs 9.9%). Furthermore, patients who developed ICH expansion had higher mortality compared with patients who had ischemic stroke while being off anticoagulation (41% vs 9%). Use of intravenous heparin bridging upon resumption of warfarin was strongly associated with increased risk of ICH expansion as compared with restarting warfarin without a heparin bridge. DISCUSSION: Withholding anticoagulation for at least 7 days after ICH may be safe in patients with mechanical heart valves. Heparin bridging during anticoagulation resumption may be associated with increased risk of bleeding.
引用
- Sakusic A, Rabinstein AA, Anisetti B, et al. Timing of Anticoagulation Resumption and Risk of Ischemic and Hemorrhagic Complications in Patients With ICH and Mechanical Heart Valves. Neurology. 2024. PMID: 39102615. doi:10.1212/WNL.0000000000209664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。